WA42294 PRM-151: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)

Administered By

Awarded By

Contributors

Start/End

  • March 16, 2022 - March 15, 2027